Waypoint Bio raised $20 million in Series A funding to test multiple CAR-T programs in China, according to company-reported plans. The New York City startup said the financing is intended to support development execution in the Chinese clinical testing environment. The company’s approach targets cell-therapy trials with a geographic strategy aimed at accessing China’s testing pathways while building a portfolio of programs. For investors, the round signals continued demand for early-stage cell therapy execution capabilities tied to multinational development strategies. As CAR-T development expands beyond a handful of targets, the funding reinforces how clinical throughput and regional regulatory logistics can shape where next-generation programs are launched.